StreetInsider.com  Oct 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/WHO+Says++NewLink%27s+%28NLNK%29+Experimental+Ebola+Vaccine+Will+Arrive+in+Geneva+Today/9925756.html for the full story.
Benzinga  Oct 21  Comment 
Guy Adami spoke on CNBC's Stock Pops & Drops about a 7.12 percent increase in price in NewLink Genetics Corp (NASDAQ: NLNK). He explained that the stock traded higher on the news of the signing of a deal with Genentech and he speculated that a...
TheStreet.com  Oct 20  Comment 
NEW YORK (TheStreet) -- Shares of NewLink Genetics Corp. are up 19.93% to $35.20 after the companyasaid it entered into an agreement with Roche Holding ato develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to...
Benzinga  Oct 20  Comment 
NewLink Genetics (NASDAQ: NLNK) shares moved up 19.69% to $35.13. The volume of NewLink Genetics shares traded was 629% higher than normal. NewLink Genetics announced an exclusive worldwide licensing agreement for development of NLG919 and...
Reuters  Oct 20  Comment 
NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1...
Benzinga  Oct 20  Comment 
NewLink Genetics Corporation (Nasdaq: NLNK), a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that they have entered...
Benzinga  Oct 16  Comment 
Chesapeake Energy (NYSE: CHK) shares moved up 13.11% to $20.10. The volume of Chesapeake Energy shares traded was 435% higher than normal. Chesapeake Energy announced the sale of Southern Marcellus and Utica Shale assets for $5.375...
MarketWatch  Oct 13  Comment 
Shares of Newlink Genetics Corp. surged Monday after Canadian health officials said they were beginning early-stage clinical trials on an Ebola vaccine that is licensed to the Ames, Iowa-based biotech. Shares of Newlink closed up 24% at $22.42 on...
Benzinga  Oct 8  Comment 
The Texas Health Presbyterian Hospital issued a press release Wednesday announcing that the Ebola patient Eric Duncan has died. It appears this is the first case of an Ebola death in the United States. Shares of Ebola-related stocks have...
StreetInsider.com  Oct 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Cantor+Fitzgerald+Analyt+Comments+on+NewLink+Genetics+%28NLNK%29+CFO+Change/9879657.html for the full story.


NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical which develops drugs to help treat cancer patients.[1] The company focuses on immunotherapy - or treatment by causing the immune system to either act or cease to act. In other words, NewLink Genetics attempts to encourage the patients immune system to combat the cancerous cells rather than attempting to kill the cells directly.[2] NewLink Genetics revenues are dependent on the discovery and FDA approval of its therapies.

Business Overview

For the full year 2010, NewLink generated $2.1M in grant revenue. This was an over 100% increase from the $.9M in 2009. Since the company spends heavily on research and development, it still reported a net loss for 2010 of $16.6M. This compares to a net loss of $10.2M in 2009. [3]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on November 10, 2011. The company offered 6.2M shares each for $7. The company had already planned to sell 5.5M shares. However, since they priced below the $10-$12 range, they increased shares. The deal raised a total of $43M. The lead mangers of the deal were Stifel Financial (SF) and Canaccord Genuity.[4]

Trends & Forces

Dependence on FDA approval

As of its IPO, NewLink did not have any FDA approved drugs. It's quite clear that without a completed drug, the company will be unable to produce substantial operating revenue. As a result, the company's performance is limited to actions from the FDA. Furthermore, since NewLink is in the process of developing new, untested treatments, there is no clear guidance for the likelihood of approval or the likelihood that physicians will adopt new treatments.[5]

  1. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Overview p. 1
  2. American Cancer Society - Find Support and Treatment "Immunotherapy"
  3. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Selected Financial Data p. 51
  4. Renaissance Capital - IPO Home "NewLink Genetics prices IPO at $7, below the range" 11 Nov 2011
  5. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Risk Factors" pp. 11-15
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki